Table of Contents

1 Report Overview

• 1.1 Study Scope
• 1.2 Major Manufacturers Covered in This Report
• 1.3 Market Segment by Type
  • 1.3.1 Global Drug Repurposing Market Size Growth Rate by Type (2019-2025)
  • 1.3.2 Oncology
  • 1.3.3 CNS Diseases
  • 1.3.4 Neurodegenerative Diseases
  • 1.3.5 Others
• 1.4 Market Segment by Application
  • 1.4.1 Global Drug Repurposing Market Share by Application (2019-2025)
  • 1.4.2 Hospitals
  • 1.4.3 Ambulatory Surgical Centers
  • 1.4.4 Others
• 1.5 Study Objectives
• 1.6 Years Considered

2 Global Growth Trends

• 2.1 Global Drug Repurposing Market Size
  • 2.1.1 Global Drug Repurposing Revenue 2014-2025
  • 2.1.2 Global Drug Repurposing Sales 2014-2025
• 2.2 Drug Repurposing Growth Rate by Regions
  • 2.2.1 Global Drug Repurposing Sales by Regions 2014-2019
  • 2.2.2 Global Drug Repurposing Revenue by Regions 2014-2019
• 2.3 Industry Trends
  • 2.3.1 Market Top Trends
  • 2.3.2 Market Drivers

3 Market Share by Manufacturers

• 3.1 Drug Repurposing Sales by Manufacturers
  • 3.1.1 Drug Repurposing Sales by Manufacturers 2014-2019
  • 3.1.2 Drug Repurposing Sales Market Share by Manufacturers 2014-2019
• 3.2 Revenue by Manufacturers
  • 3.2.1 Drug Repurposing Revenue by Manufacturers (2014-2019)
  • 3.2.2 Drug Repurposing Revenue Share by Manufacturers (2014-2019)
  • 3.2.3 Global Drug Repurposing Market Concentration Ratio (CR5 and HHI)
• 3.3 Drug Repurposing Price by Manufacturers
• 3.4 Key Manufacturers Drug Repurposing Plants/Factories Distribution and Area Served
• 3.5 Date of Key Manufacturers Enter into Drug Repurposing Market
• 3.6 Key Manufacturers Drug Repurposing Product Offered
• 3.7 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type

• 4.1 Sales and Revenue for Each Type
  • 4.1.1 Oncology Sales and Revenue (2014-2019)
  • 4.1.2 CNS Diseases Sales and Revenue (2014-2019)
  • 4.1.3 Neurodegenerative Diseases Sales and Revenue (2014-2019)
  • 4.1.4 Others Sales and Revenue (2014-2019)
• 4.2 Global Drug Repurposing Sales Market Share by Type
• 4.3 Global Drug Repurposing Revenue Market Share by Type
• 4.4 Drug Repurposing Price by Type

5 Market Size by Application

• 5.1 Overview
• 5.2 Global Drug Repurposing Sales by Application

6 United States

• 6.1 United States Drug Repurposing Breakdown Data by Company
• 6.2 United States Drug Repurposing Breakdown Data by Type
• 6.3 United States Drug Repurposing Breakdown Data by Application

7 European Union

• 7.1 European Union Drug Repurposing Breakdown Data by Company
• 7.2 European Union Drug Repurposing Breakdown Data by Type
• 7.3 European Union Drug Repurposing Breakdown Data by Application

8 China

• 8.1 China Drug Repurposing Breakdown Data by Company
• 8.2 China Drug Repurposing Breakdown Data by Type
• 8.3 China Drug Repurposing Breakdown Data by Application

9 Rest of World

• 9.1 Rest of World Drug Repurposing Breakdown Data by Company
• 9.2 Rest of World Drug Repurposing Breakdown Data by Type
• 9.3 Rest of World Drug Repurposing Breakdown Data by Application
• 9.4 Rest of World Drug Repurposing Breakdown Data by Countries
  • 9.4.1 Rest of World Drug Repurposing Sales by Countries
  • 9.4.2 Rest of World Drug Repurposing Revenue by Countries
  • 9.4.3 Japan
  • 9.4.4 Korea
  • 9.4.5 India
  • 9.4.6 Southeast Asia

10 Company Profiles

• 10.1 Astellas Pharma
  • 10.1.1 Astellas Pharma Company Details
  • 10.1.2 Company Description and Business Overview
  • 10.1.3 Sales, Revenue and Market Share of Drug Repurposing
  • 10.1.4 Drug Repurposing Product Introduction
  • 10.1.5 Astellas Pharma Recent Development
• 10.2 Biovista
  • 10.2.1 Biovista Company Details
  • 10.2.2 Company Description and Business Overview
  • 10.2.3 Sales, Revenue and Market Share of Drug Repurposing
  • 10.2.4 Drug Repurposing Product Introduction
  • 10.2.5 Biovista Recent Development
• 10.3 Novartis
  • 10.3.1 Novartis Company Details
  • 10.3.2 Company Description and Business Overview
  • 10.3.3 Sales, Revenue and Market Share of Drug Repurposing
  • 10.3.4 Drug Repurposing Product Introduction
  • 10.3.5 Novartis Recent Development
• 10.4 AbbVie
  • 10.4.1 AbbVie Company Details
  • 10.4.2 Company Description and Business Overview
  • 10.4.3 Sales, Revenue and Market Share of Drug Repurposing
  • 10.4.4 Drug Repurposing Product Introduction
  • 10.4.5 AbbVie Recent Development
• 10.5 Pfizer
  • 10.5.1 Pfizer Company Details
  • 10.5.2 Company Description and Business Overview
  • 10.5.3 Sales, Revenue and Market Share of Drug Repurposing
  • 10.5.4 Drug Repurposing Product Introduction
  • 10.5.5 Pfizer Recent Development
• 10.6 Allergan
  • 10.6.1 Allergan Company Details
  • 10.6.2 Company Description and Business Overview
  • 10.6.3 Sales, Revenue and Market Share of Drug Repurposing
  • 10.6.4 Drug Repurposing Product Introduction
  • 10.6.5 Allergan Recent Development
• 10.7 NuMedii
  • 10.7.1 NuMedii Company Details
  • 10.7.2 Company Description and Business Overview
  • 10.7.3 Sales, Revenue and Market Share of Drug Repurposing
  • 10.7.4 Drug Repurposing Product Introduction
  • 10.7.5 NuMedii Recent Development

11 Value Chain and Sales Channels Analysis

• 11.1 Value Chain Analysis
• 11.2 Sales Channels Analysis
  • 11.2.1 Drug Repurposing Sales Channels
  • 11.2.2 Drug Repurposing Distributors
• 11.3 Drug Repurposing Customers

12 Market Forecast

• 12.1 Global Drug Repurposing Sales and Revenue Forecast 2019-2025
• 12.2 Global Drug Repurposing Sales Forecast by Type
• 12.3 Global Drug Repurposing Sales Forecast by Application
• 12.4 Drug Repurposing Forecast by Regions
  • 12.4.1 Global Drug Repurposing Sales Forecast by Regions 2019-2025
  • 12.4.2 Global Drug Repurposing Revenue Forecast by Regions 2019-2025
• 12.5 United States Market Forecast
• 12.6 European Union Market Forecast
• 12.7 China Market Forecast
• 12.8 Rest of World
  • 12.8.1 Japan
  • 12.8.2 Korea
  • 12.8.3 India

13 Research Findings and Conclusion

14 Appendix

• 14.1 Research Methodology
  • 14.1.1 Methodology/Research Approach
    • 14.1.1.1 Research Programs/Design
    • 14.1.1.2 Market Size Estimation
    • 14.1.1.3 Market Breakdown and Data Triangulation
  • 14.1.2 Data Source
    • 14.1.2.1 Secondary Sources
    • 14.1.2.2 Primary Sources
• 14.2 Author Details

Drug repurposing or re-profiling has been the hallmark to bring strong business growth and the trend is being followed by majority of the pharmaceutical and biopharmaceutical companies. Among all biologics approved in the U.S. during 2007-2009, 30-40% of them were the drugs repurposed or repositioned. National Institute of Health (NIH), U.S. Department of Health defines drug repurposing as discovering new uses for approved drugs to provide the quickest possible transition from bench to bedside. Drug repurposing opens up various opportunities to answer current unmet medical needs to come up with cost-effective solutions to expensive drug development process. Repurposing or re-profiling of drugs which are suspended due to lack of efficacy or specificity can be a good start over for further development for new indication. Finding new indications for already studied drugs can benefit patients by getting quick access to new treatment choices and also to developer by saving time and money while maintaining its original IP protection. For many expensive indications such as cancer, scrutinizing for anti-cancer activity among dozens of off-patent drugs that have already established their safety is a powerful method opted by majority of the big pharma companies. However, repurposing is not a new strategy and there are bunch of drugs which are repositioned or repurposed, some of them are Raloxifene (approved for treatment of osteoporosis in 2007, originally indicated for breast cancer treatment), Thalidomide (repositioned for use in treatment of leprosy and multiple myeloma in 2006), Rapamycin (repurposed in 1999 for prevention of organ transplant rejection), Sildenafil (originally approved for erectile dysfunction and recently got approved for treatment of angina) and many others.
Requirement of low investment of time and money in the drug development is the prime advantage of drug repurposing and majority of the drugs in pipeline of major pharmaceutical companies are thus adopt this method. Some of the factors accelerating the drug repurposing activities include sunk research cost, ready availably of bioavailability, pharmacology, toxicity profile & pharmacokinetics data, well established manufacturing protocol etc.; which are expected to drive the global drug repurposing market. There are thousands of failed molecules shelved into the drug libraries, which hold vast potential to reposition. Whereas, limited access chemical structure data of drug molecules, lack of funding etc. are some of the factors limiting the growth of global drug repurposing market.
In 2019, the market size of Drug Repurposing is xx million US$ and it will reach xx million US$ in 2025, growing at a CAGR of xx% from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Drug Repurposing.

This report studies the global market size of Drug Repurposing, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
This study presents the Drug Repurposing sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.

In global market, the following companies are covered:
Astellas Pharma
Biovista
Novartis
AbbVie
Pfizer
Allergan
NuMedii
...

Market Segment by Product Type
Oncology
CNS Diseases
Neurodegenerative Diseases
Others

Market Segment by Application
Hospitals
Ambulatory Surgical Centers
Others

Key Regions split in this report: breakdown data for each region.
United States
China
European Union
Rest of World (Japan, Korea, India and Southeast Asia)

The study objectives are:
To analyze and research the Drug Repurposing status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
To present the key Drug Repurposing manufacturers, presenting the sales, revenue, market share, and recent development for key players.
To split the breakdown data by regions, type, companies and applications
To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
To identify significant trends, drivers, influence factors in global and regions
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market

In this study, the years considered to estimate the market size of Drug Repurposing are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025